Virpax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VRPX) $0.44 +0.05 (+12.66%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.38▼$0.4550-Day Range$0.39▼$0.8252-Week Range$0.32▼$1.20Volume697,206 shsAverage Volume35,803 shsMarket Capitalization$5.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Read More VRPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRPX Stock News HeadlinesNovember 22, 2023 | seekingalpha.comVRPX Virpax Pharmaceuticals, Inc.November 18, 2023 | markets.businessinsider.comPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax PharmaceuticalsDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 17, 2023 | msn.comVirpax Pharmaceuticals gets non-compliance notice from NasdaqNovember 17, 2023 | msn.comVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Leadership TransitionNovember 17, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingNovember 15, 2023 | msn.comVirpax Pharmaceuticals GAAP EPS of -$0.51December 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewSeptember 28, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)September 27, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesSeptember 26, 2023 | finance.yahoo.comVirpax Pharmaceuticals to Present at the LD Micro Main Event XVISeptember 21, 2023 | businesswire.comAltasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like VirusesSeptember 18, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces the Formation of Novvae™ PharmaceuticalsSeptember 5, 2023 | msn.comVirpax slips as court rules in favor of Scilex and SorrentoAugust 28, 2023 | finance.yahoo.comVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Virpax Pharmaceuticals (VRPX)August 10, 2023 | finance.yahoo.comVirpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and MethodJuly 24, 2023 | finance.yahoo.comVirpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023July 13, 2023 | finance.yahoo.comVirpax Pharmaceuticals Files Provisional Patent Application for Intranasal DeliveryJune 21, 2023 | finance.yahoo.comVirpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke CouncilJune 20, 2023 | finance.yahoo.comVirpax Pharmaceuticals Announces CFO TransitionJune 13, 2023 | finance.yahoo.comVirpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETMay 12, 2023 | msn.comVirpax Pharmaceuticals GAAP EPS of -$0.13 beats by $0.17May 10, 2023 | finance.yahoo.comVirpax Pharmaceuticals To Present at Upcoming CB Tech Watch SeminarMay 4, 2023 | finance.yahoo.comVirpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023See More Headlines Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRPX CUSIPN/A CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.65% Return on Assets-75.47% Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick Ratio4.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.31Miscellaneous Outstanding Shares11,710,000Free Float8,176,000Market Cap$5.21 million OptionableNot Optionable Beta1.48 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Anthony P. Mack M.B.A. (Age 61)Chairman & CEO Comp: $705kDr. Jeffrey A. Gudin M.D. (Age 57)Executive VP, Chief Medical Officer & Director Comp: $204kMr. Gerald W. Bruce (Age 66)Executive VP of Commercial Operations & Director Mr. Vinay Shah A.C.A. (Age 61)M.B.A., CFO, Principal Financial Officer & Principal Accounting Officer Dr. Sheila A. Mathias J.D.M.B.A., Ph.D., Chief Scientific OfficerShana PanzarellaChief of StaffMore ExecutivesKey CompetitorsTransCode TherapeuticsNASDAQ:RNAZAddex TherapeuticsNASDAQ:ADXNHoth TherapeuticsNASDAQ:HOTHXenetic BiosciencesNASDAQ:XBIOSynaptogenixNASDAQ:SNPXView All CompetitorsInstitutional OwnershipSabby Management LLCSold 107,210 shares on 11/15/2023Ownership: 2.500%View All Institutional Transactions VRPX Stock Analysis - Frequently Asked Questions How have VRPX shares performed in 2023? Virpax Pharmaceuticals' stock was trading at $0.6223 at the beginning of the year. Since then, VRPX stock has decreased by 28.5% and is now trading at $0.4450. View the best growth stocks for 2023 here. When is Virpax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our VRPX earnings forecast. When did Virpax Pharmaceuticals IPO? (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. Who are Virpax Pharmaceuticals' major shareholders? Virpax Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (2.50%). Insiders that own company stock include Anthony P Mack, Eric Floyd, Jerrold Sendrow and Thani Jambulingam. View institutional ownership trends. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:VRPX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.